Payment overview · 2025
General Payments
$536.60
24 reported records · 18 companies
Healthcare provider profile · identity verified
Jason B Jerabek, DO
Allopathic & Osteopathic Physicians|Family Medicine · CHARLESTON, IL · NPI 1396853008
Verified facts
What the public records show
CMS Open Payments records show Jason B Jerabek, DO received $536.60 in general payments during 2025 across 24 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $111.47 | 20.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $64.20 | 12.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $57.49 | 10.7% | 3 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $39.89 | 7.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.17 | 4.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.79 | 4.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.13 | 4.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $21.21 | 4.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.49 | 3.8% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $18.93 | 3.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.87 | 3.5% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $18.20 | 3.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.44 | 3.2% | 1 | 2025 |
| Itamar Medical Inc | Unresolved — no canonical attribution shown | $17.40 | 3.2% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $16.54 | 3.1% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $15.19 | 2.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.12 | 2.6% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $14.07 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $536.60 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $95.20 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $64.20 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $45.60 | 3 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $39.89 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $39.89 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $23.79 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $23.13 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $21.21 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.49 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| WatchPATONE Normalized: watchpatone |
Device | Itamar Medical Inc | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 71 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 111 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
97 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
111 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
97 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 571 | 80 |
| Atorvastatin Calcium | Atorvastatin Calcium | 427 | 78 |
| Omeprazole | Omeprazole | 344 | 61 |
| Lisinopril | Lisinopril | 341 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 299 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 258 | 51 |
| Potassium Chloride | Potassium Chloride | 226 | 34 |
| Metformin Hcl | Metformin Hcl | 219 | 35 |
| Famotidine | Famotidine | 217 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 209 | 44 |
| Furosemide | Furosemide | 206 | 37 |
| Montelukast Sodium | Montelukast Sodium | 204 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 200 | 51 |
| Losartan Potassium | Losartan Potassium | 200 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 175 | 27 |
| Gabapentin | Gabapentin | 168 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 145 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 141 | 23 |
| Risperidone | Risperidone | 130 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 123 | 26 |
| Simvastatin | Simvastatin | 123 | 19 |
| Tramadol Hcl | Tramadol Hcl | 120 | 28 |
| Ezetimibe | Ezetimibe | 117 | 18 |
| Atenolol | Atenolol | 112 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 112 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 111 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 106 | 24 |
| Linzess | Linaclotide | 103 | 13 |
| Eliquis | Apixaban | 97 | 21 |
| Trazodone Hcl | Trazodone Hcl | 95 | 23 |
| Levetiracetam | Levetiracetam | 94 | suppressed |
| Meloxicam | Meloxicam | 89 | 15 |
| Sertraline Hcl | Sertraline Hcl | 89 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 86 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 86 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 26 |
| Buspirone Hcl | Buspirone Hcl | 81 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 81 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 79 | 16 |
| Alendronate Sodium | Alendronate Sodium | 77 | 11 |
| Metformin Hcl Er | Metformin Hcl | 76 | 17 |
| Celecoxib | Celecoxib | 73 | 13 |
| Ozempic | Semaglutide | 71 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 14 |
| Januvia | Sitagliptin Phosphate | 69 | suppressed |
| Allopurinol | Allopurinol | 67 | 14 |
| Gemfibrozil | Gemfibrozil | 67 | suppressed |
| Alprazolam | Alprazolam | 66 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 62 | suppressed |
| Rybelsus | Semaglutide | 61 | suppressed |
| Carvedilol | Carvedilol | 59 | 13 |
| Divalproex Sodium Er | Divalproex Sodium | 59 | suppressed |
| Pregabalin | Pregabalin | 58 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 57 | suppressed |
| Azithromycin | Azithromycin | 54 | 36 |
| Prednisone | Prednisone | 54 | 32 |
| Jardiance | Empagliflozin | 51 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 45 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 45 | suppressed |
| Glipizide | Glipizide | 44 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 44 | suppressed |
| Amoxicillin | Amoxicillin | 43 | 34 |
| Warfarin Sodium | Warfarin Sodium | 43 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 41 | suppressed |
| Fenofibrate | Fenofibrate | 40 | suppressed |
| Progesterone | Progesterone, Micronized | 40 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | suppressed |
| Carbamazepine | Carbamazepine | 38 | suppressed |
| Ketoconazole | Ketoconazole | 38 | suppressed |
| Naproxen | Naproxen | 38 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 33 | suppressed |
| Estradiol | Estradiol | 33 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 33 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 32 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Glimepiride | Glimepiride | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 29 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 28 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Np Thyroid | Thyroid,pork | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Telmisartan | Telmisartan | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | 14 |
| Vilazodone Hcl | Vilazodone Hcl | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 15 |
| Lactulose | Lactulose | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Cephalexin | Cephalexin | 17 | 11 |
| Clonazepam | Clonazepam | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 12 |
| Nystatin | Nystatin | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Niacin Er | Niacin | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Praluent Pen | Alirocumab | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Etodolac | Etodolac | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $536.60 · 24 records | AstraZeneca Pharmaceuticals LP | ABILIFY MAINTENA, AIRSUPRA, ARISTADA, Auvelity, BREZTRI, COBENFY, Cologuard Collection Kit, Flexitouch Plus, GVOKE HYPOPEN, IBSRELA, INGREZZA, JARDIANCE, LYBALVI, MOUNJARO, NURTEC ODT, Nimbl, Ohtuvayre, Ozempic, TRELEGY ELLIPTA, WatchPATONE, Wegovy, YUPELRI, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error